Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up

Monica Cabrero, MD, Elias Jabbour, MD, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Jorge E. Cortes, MD, Zach Bohannan, Victoria Sukholutsky, Farhad Ravandi, MD, Sherry Pierce, BSN, BA, Tapan Kadia, MD, Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 4664.

https://doi.org/10.1182/blood.V124.21.4664.4664

Published: 2014

Journal Articles

Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study

Monica Cabrero, MD, Guillermo Garcia-Manero, MD, Koji Sasaki, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Jorge E. Cortes, MD, Zach Bohannan, Victoria Sukholutsky, Farhad Ravandi, MD, Sherry Pierce, BSN, BA, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Betul Oran, MD, Richard E. Champlin, Hagop Kantarjian, MD, Elias Jabbour, MD

Blood (2014) 124 (21): 4666.

https://doi.org/10.1182/blood.V124.21.4666.4666

Published: 2014

Journal Articles

Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications

Talha Badar, MBBS,FCPS, Philip A Thompson, MBBS, Binsah George, MD, Naval Daver, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Marina Konopleva, MD PhD, Tapan M. Kadia, MD, Zach Bohannan, Sherry Pierce, BSN, BA, Elias Jabbour, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Keyur P. Patel, MD PhD, Raja Luthra, Victoria Sukholutsky, Guillermo Garcia Manero, MD

Blood (2014) 124 (21): 4631.

https://doi.org/10.1182/blood.V124.21.4631.4631

Published: 2014

Journal Articles

Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS)

Elias Jabbour, MD, Koji Sasaki, Naval Daver, MD, Naveen Pemmaraju, MD, Courtney D. DiNardo, MD, Tapan Kadia, MD, Darla Miller, Victoria Sukholutsky, Xuelin Huang, PhD, Gautam Borthakur, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 4640.

https://doi.org/10.1182/blood.V124.21.4640.4640

Published: 2014

Journal Articles

A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities

Blood (2014) 124 (21): 3277.

https://doi.org/10.1182/blood.V124.21.3277.3277

Published: 2014

NARROW

Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up

Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study

Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications

Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS)

A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities

Email alerts

ASH Publications

American Society of Hematology

Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up

Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study

Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications

Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS)

A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only